BR112022012819A2 - Método para tratar mielofibrose em um paciente e kit - Google Patents
Método para tratar mielofibrose em um paciente e kitInfo
- Publication number
- BR112022012819A2 BR112022012819A2 BR112022012819A BR112022012819A BR112022012819A2 BR 112022012819 A2 BR112022012819 A2 BR 112022012819A2 BR 112022012819 A BR112022012819 A BR 112022012819A BR 112022012819 A BR112022012819 A BR 112022012819A BR 112022012819 A2 BR112022012819 A2 BR 112022012819A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- kit
- myelofibrosis
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 206010028537 myelofibrosis Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 abstract 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 abstract 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 abstract 1
- 229960000215 ruxolitinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953654P | 2019-12-26 | 2019-12-26 | |
| PCT/US2020/066762 WO2021133866A1 (en) | 2019-12-26 | 2020-12-23 | Compounds for the treatment of myelofibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012819A2 true BR112022012819A2 (pt) | 2022-09-06 |
Family
ID=74186982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012819A BR112022012819A2 (pt) | 2019-12-26 | 2020-12-23 | Método para tratar mielofibrose em um paciente e kit |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230062278A1 (https=) |
| EP (1) | EP4081213A1 (https=) |
| JP (1) | JP2023508491A (https=) |
| KR (1) | KR20230005808A (https=) |
| CN (1) | CN115697323A (https=) |
| AU (1) | AU2020415440A1 (https=) |
| BR (1) | BR112022012819A2 (https=) |
| CA (1) | CA3166251A1 (https=) |
| IL (1) | IL294369A (https=) |
| MX (1) | MX2022008046A (https=) |
| WO (1) | WO2021133866A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2673368C (en) * | 2006-12-19 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| CN113384546A (zh) * | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| CN106349224A (zh) * | 2016-08-03 | 2017-01-25 | 山东大学 | 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用 |
| WO2019222483A1 (en) * | 2018-05-17 | 2019-11-21 | Board Of Regents, The University Of Texas System | Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors |
| CN112351819B (zh) * | 2018-06-05 | 2023-11-10 | 开动疗法公司 | 治疗恶性淋巴增生性疾病的方法 |
-
2020
- 2020-12-23 AU AU2020415440A patent/AU2020415440A1/en not_active Abandoned
- 2020-12-23 MX MX2022008046A patent/MX2022008046A/es unknown
- 2020-12-23 EP EP20842523.1A patent/EP4081213A1/en not_active Withdrawn
- 2020-12-23 US US17/789,321 patent/US20230062278A1/en not_active Abandoned
- 2020-12-23 BR BR112022012819A patent/BR112022012819A2/pt not_active Application Discontinuation
- 2020-12-23 WO PCT/US2020/066762 patent/WO2021133866A1/en not_active Ceased
- 2020-12-23 IL IL294369A patent/IL294369A/en unknown
- 2020-12-23 KR KR1020227025801A patent/KR20230005808A/ko not_active Withdrawn
- 2020-12-23 CN CN202080094791.2A patent/CN115697323A/zh active Pending
- 2020-12-23 CA CA3166251A patent/CA3166251A1/en active Pending
- 2020-12-23 JP JP2022539641A patent/JP2023508491A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115697323A (zh) | 2023-02-03 |
| CA3166251A1 (en) | 2021-07-01 |
| IL294369A (en) | 2022-08-01 |
| JP2023508491A (ja) | 2023-03-02 |
| MX2022008046A (es) | 2022-11-14 |
| WO2021133866A1 (en) | 2021-07-01 |
| EP4081213A1 (en) | 2022-11-02 |
| US20230062278A1 (en) | 2023-03-02 |
| AU2020415440A1 (en) | 2022-08-04 |
| KR20230005808A (ko) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008777A (es) | Inmunoterapias relacionadas con el microbioma. | |
| MY206748A (en) | Antibodies that target hiv gp120 and methods of use | |
| BR112022002609A2 (pt) | Métodos de tratamento de tumores estromais gastrointestinais | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| BR112014015482A8 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| MX348898B (es) | Métodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales. | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| BR112013007423A2 (pt) | terapia combinada no que diz respeito ao tratamento da infecção por hcv | |
| MX2021008010A (es) | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). | |
| JOP20230276A1 (ar) | تركيبات وطرق لعلاج الاكتئاب | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| CO2022001354A2 (es) | Métodos para tratar o prevenir la atrofia muscular espinal | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| CL2021000743A1 (es) | Métodos para tratar trastornos mieloproliferativos | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2025004900A (es) | Tratamiento de verrugas | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |